Abstract
ABSTRACTObjective:Our aim was to analyze the effectiveness of oxybutynin for hyperhidrosis treatment in patients over 40 years.Methods:Eighty-seven patients aged over 40 years were divided into two groups. One group consisted of 48 (55.2%) patients aged between 40 and 49 years, and another was composed of 39 (44.8%) patients aged over 50 years (50 to 74 years). A comparative analysis of Quality of Life and level of hyperhidrosis between the groups was carried out 6 weeks after a protocol treatment with oxybutynin. A validated clinical questionnaire was used for evaluation.Results:In the younger age group, 75% of patients referred a “partial” or “great” improvement in level of hyperhidrosis after treatment. This number was particularly impressive in patients over 50 years, in which 87.2% of the cases demonstrated similar levels of improvement. Over 77% of patients in both groups demonstrated improvement in Quality of Life. Excellent outcomes were observed in older patients, in which 87.1% of patients presented “slightly better” (41%) or “much better” (46.1%) improvement.Conclusion:Patients aged over 40 years with hyperhidrosis presented excellent results after oxybutynin treatment. These outcomes were particularly impressive in the age group over 50 years, in which most patients had significant improvement in Quality of Life and in level of hyperhidrosis.
Highlights
Primary hyperhidrosis is a condition known for excessive sweating, beyond the body’s physiologic needs[1] that impacts in Quality of Life (QOL).(2) A greater knowledge of the disease associated with upcoming therapeutic possibilities increased patient demand for treatment
It was demonstrated that patients with primary hyperhidrosis have a higher expression of acetylcholine and alpha-7 nicotinic receptors in sympathetic ganglia.[5]. Oxybutynin is an antimuscarinic drug that was first associated to hyperhidrosis in 1988.(6) In the second half of the last decade, specific treatment with this drug began to be reported.[7,8] Its use was studied for specificsite hyperhidrosis: axillary,(9) facial,(10) palmar[11] and plantar,(12) all with good results
Age, site of hyperhidrosis, body mass index (BMI) distribution and gender of the studied population are demonstrated on table 1
Summary
Primary hyperhidrosis is a condition known for excessive sweating, beyond the body’s physiologic needs[1] that impacts in Quality of Life (QOL).(2) A greater knowledge of the disease associated with upcoming therapeutic possibilities increased patient demand for treatment. It was demonstrated that patients with primary hyperhidrosis have a higher expression of acetylcholine and alpha-7 nicotinic receptors in sympathetic ganglia.[5] Oxybutynin is an antimuscarinic drug that was first associated to hyperhidrosis in 1988.(6) In the second half of the last decade, specific treatment with this drug began to be reported.[7,8] Its use was studied for specificsite hyperhidrosis: axillary,(9) facial,(10) palmar[11] and plantar,(12) all with good results. The first randomized placebo-controlled trial was reported in 2012,(13) for analysis of the initial treatment of palmar and axillary hyperhidrosis, with improvement in over 70% of patients when compared to placebo. This medication has been increasingly used as an initial or alternative therapy, especially in older patients who are not candidates for surgery. Studies analyzing benefit of this medication for patients over 40 years have not been carried out
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
